HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
Marco Venturini(Ente Ospedaliero Ospedali Galliera), A Lavarello(Azienda Sanitaria Locale di Asti), Claudia Bighin(Azienda Ospedaliera S.Maria), Paolo Bruzzi(Alleanza Contro il Cancro), Giovanna Cavazzini(University of Padua), Mauro D’Amico(Ente Ospedaliero Ospedali Galliera), B. Castagneto(Azienda Ospedaliera Carlo Poma), R. Rosso(Research Institute for Geo-Hydrological Protection), Lucia Del Mastro(Ospedale Policlinico San Martino), Franco Testore(Ente Ospedaliero Ospedali Galliera), Luisa Perdelli(National Cancer Research Institute), Enrico Aitini, A. Contu(Ente Ospedaliero Ospedali Galliera), Guido Nicolò(Azienda Ospedaliera Carlo Poma)
Cited by 39
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Trends and challenges in the operation of pumped-storage hydropower plants
|Renewable and Sustainable Energy Reviews|2015|315
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282